Feclobuzone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C27H25ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6889JIL5D, chemically known as 4-chlorbenzoesaeure ester mil 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidindion but generally known as feclobuzone, which bears US NIH Compound Identifier 176165. European Medicines Agency schedules Feclobuzone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07523MIG. The term FECLOBUZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, No. 10 1972, List 12). FECLOBUZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule feclobuzone under HS 29331990 and SITC 51571. As of Q4 2014, FECLOBUZONE remains the US FDA Preferred Term for this commodity. Feclobuzone bears US NLM identifiers UMLS ID C1880740 and NCI Concept Code C65631. SMILES: CLC1CCC(C(=O)OCC2(CCCC)C(=O)N(N(C2=O)C2CCCCC2)C2CCCCC2)CC1.